289 related articles for article (PubMed ID: 25099612)
21. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
Schultheis B; Reuter D; Ebert MP; Siveke J; Kerkhoff A; Berdel WE; Hofheinz R; Behringer DM; Schmidt WE; Goker E; De Dosso S; Kneba M; Yalcin S; Overkamp F; Schlegel F; Dommach M; Rohrberg R; Steinmetz T; Bulitta M; Strumberg D
Ann Oncol; 2017 Oct; 28(10):2429-2435. PubMed ID: 28961832
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Hensley ML; Miller A; O'Malley DM; Mannel RS; Behbakht K; Bakkum-Gamez JN; Michael H
J Clin Oncol; 2015 Apr; 33(10):1180-5. PubMed ID: 25713428
[TBL] [Abstract][Full Text] [Related]
24. Combined associations of 25-hydroxivitamin D and parathyroid hormone with diabetes risk and associated comorbidities among U.S. white and black women.
Xia J; Tu W; Manson JE; Nan H; Shadyab AH; Bea JW; Gower EW; Qi L; Cheng TD; Song Y
Nutr Diabetes; 2021 Sep; 11(1):29. PubMed ID: 34531372
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
26. Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).
Yuan C; Sato K; Hollis BW; Zhang S; Niedzwiecki D; Ou FS; Chang IW; O'Neil BH; Innocenti F; Lenz HJ; Blanke CD; Goldberg RM; Venook AP; Mayer RJ; Fuchs CS; Meyerhardt JA; Ng K
Clin Cancer Res; 2019 Dec; 25(24):7497-7505. PubMed ID: 31548349
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Jin SF; Fan ZK; Pan L; Jin LM
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer.
Sahora K; Schindl M; Kuehrer I; Eisenhut A; Werba G; Brostjan C; Telek B; Ba'ssalamah A; Stift J; Schoppmann SF; Gnant M
Anticancer Res; 2014 May; 34(5):2377-84. PubMed ID: 24778046
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.
Su D; Jiao SC; Wang LJ; Shi WW; Long YY; Li J; Bai L
Tumour Biol; 2014 Mar; 35(3):2313-8. PubMed ID: 24142531
[TBL] [Abstract][Full Text] [Related]
31. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK
Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
[TBL] [Abstract][Full Text] [Related]
33. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract][Full Text] [Related]
34. Seasonal variation of 25-hydroxyvitamin D among non-Hispanic black and white pregnant women from three US pregnancy cohorts.
Luque-Fernandez MA; Gelaye B; VanderWeele T; Ferre C; Siega-Riz AM; Holzman C; Enquobahrie DA; Dole N; Williams MA
Paediatr Perinat Epidemiol; 2014 Mar; 28(2):166-76. PubMed ID: 24354847
[TBL] [Abstract][Full Text] [Related]
35. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.
Drake MT; Maurer MJ; Link BK; Habermann TM; Ansell SM; Micallef IN; Kelly JL; Macon WR; Nowakowski GS; Inwards DJ; Johnston PB; Singh RJ; Allmer C; Slager SL; Weiner GJ; Witzig TE; Cerhan JR
J Clin Oncol; 2010 Sep; 28(27):4191-8. PubMed ID: 20713849
[TBL] [Abstract][Full Text] [Related]
36. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
37. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Hammel P; Huguet F; van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C;
JAMA; 2016 May; 315(17):1844-53. PubMed ID: 27139057
[TBL] [Abstract][Full Text] [Related]
38. Serum 25-hydroxyvitamin D is associated with incident peripheral artery disease among white and black adults in the ARIC study cohort.
Rapson IR; Michos ED; Alonso A; Hirsch AT; Matsushita K; Reis JP; Lutsey PL
Atherosclerosis; 2017 Feb; 257():123-129. PubMed ID: 28131046
[TBL] [Abstract][Full Text] [Related]
39. Association of 25-hydroxyvitamin D with areal and volumetric measures of bone mineral density and parathyroid hormone: impact of vitamin D-binding protein and its assays.
Jemielita TO; Leonard MB; Baker J; Sayed S; Zemel BS; Shults J; Herskovitz R; Denburg MR
Osteoporos Int; 2016 Feb; 27(2):617-26. PubMed ID: 26359185
[TBL] [Abstract][Full Text] [Related]
40. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
